Literature DB >> 20731616

Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.

Zhe Yang1, Lin Zhou, Li-Ming Wu, Hai-Yang Xie, Feng Zhang, Shu-Sen Zheng.   

Abstract

BACKGROUND: Histone deacetylases (HDACs) have been reported to be poor prognostic indicators in patients with cancer. However, no data are available for the role of single nucleotide polymorphism (SNP) of class I HDAC in hepato-cellular carcinoma (HCC). Therefore, we investigated the association of class I HDAC isoforms genomic polymorphisms with risk of HCC and tumor recurrence following liver transplantation (LT).
METHODS: One hundred and ninety-six Chinese subjects consisting of 97 HCC patients and 99 controls were enrolled in this study. Nine polymorphisms of the HDAC1, HDAC2, and HDAC3 gene (rs2530223, rs1741981, rs2547547, rs13204445, rs6568819, rs10499080, rs11741808, rs2475631, rs11391) were examined using Applied Biosystems SNaP-Shot and TaqMan technology.
RESULTS: We found no significant difference in genotype frequencies between the HCC cases and controls. In terms of tumor recurrence following LT, patients carrying the T allele of HDAC1 SNP rs1741981 showed a favorable outcome for recurrence free survival when compared with patients homozygous for CC. In addition, the same significant trend was observed in HDAC3 SNP rs2547547. Kaplan-Meier analysis showed that the combination of the T variant allele (CT+TT) of HDAC1 SNP rs1741981 and the homozygous TT variant allele of HDAC3 SNP rs2547547 was the most favorable prognostic factor. The risk for postoperative tumor recurrence was about 2.2-fold lower for patients with this genotype combination compared with carriers of the HDAC1 SNP rs1741981 CC and HDAC3 SNP rs2547547 CT genotype combination (hazard ratio: 2.235, p=0.003).
CONCLUSIONS: Our data suggest that combined analysis of HDAC1 SNP rs1741981 and HDAC3 SNP rs2547547 may be a potential genetic marker for HCC recurrence in LT patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731616     DOI: 10.1515/CCLM.2010.353

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  4 in total

1.  The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.

Authors:  Jian Wu; Chengli Du; Zhen Lv; Chaofeng Ding; Jun Cheng; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  Dig Dis Sci       Date:  2013-12       Impact factor: 3.199

2.  Significance of genetic variants in DLC1 and their association with hepatocellular carcinoma.

Authors:  Cheng-Rong Xie; Hong-Guang Sun; Yu Sun; Wen-Xiu Zhao; Sheng Zhang; Xiao-Min Wang; Zhen-Yu Yin
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

3.  Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.

Authors:  Dongfang Tang; Yu Chen Zhao; Danwen Qian; Hongliang Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Carolyn Glass; Wen Gao; Qingyi Wei
Journal:  Mol Carcinog       Date:  2019-11-12       Impact factor: 5.139

4.  Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.

Authors:  Xiaoyang Li; Elizabeth S Inks; Xiaoguang Li; Jinning Hou; C James Chou; Jian Zhang; Yuqi Jiang; Yingjie Zhang; Wenfang Xu
Journal:  J Med Chem       Date:  2014-04-15       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.